《2009APA急性應(yīng)激障礙和創(chuàng)傷后應(yīng)激障礙治療指南》內(nèi)容簡(jiǎn)介：

    In a 2006 Cochrane meta-**ysis, Stein et al. （4） re-viewed 35 short-term randomized controlled trials （of14 or fewer weeks in duration） involving a total of 4,597participants. In 17 of the trials, symptom severity was sig-nificantly reduced in the medication groups relative toplacebo. Evidence of efficacy was most convincing for theSSRIs, across all symptom clusters and for co-occurringdepression and disability.

    《2009APA急性應(yīng)激障礙和創(chuàng)傷后應(yīng)激障礙治療指南》內(nèi)容預(yù)覽：

    In a 2006 re**ysis of two previously published trials,Stein et al. （6） examined 395 ** patients with PTSD whowere randomized to double-blind treatment with flexiblydosed sertraline （50–200 mg/day） or placebo. After 12weeks, sertraline was significantly more effective than pla-cebo on most primary efficacy variables including Part 2 ofthe CAPS, irrespective of whether the patients had expe-rienced childhood abuse or interpersonal trauma, suggest-ing the utility of medication treatment in individualswhose precipitating trauma is either childhood abuse inparticular or interpersonal trauma in general.

    In a 2005 study, Davidson et al. （7） compared the relapserates of 57 of 62 total patients who responded to 6 monthsof open-label fluoxetine and who were subsequently blindlyrandomized to continue receiving fluoxetine （mean dosage =42.1 mg/day） or placebo. Relapse rates were 22% for flu-oxetine compared with 50% for placebo （p=0.02）； the oddsratio for relapse on placebo relative to fluoxetine was 3.50,and time to relapse on fluoxetine was longer than on pla-cebo （p = 0.02, log rank statistic）。

    點(diǎn)擊下載***：《2009APA急性應(yīng)激障礙和創(chuàng)傷后應(yīng)激障礙治療指南》